Simplifying flu vaccination for providers

With the FDA approval of an expanded indication for FLUARIX QUADRIVALENT in January 2018, GSK can now offer two flu vaccines that enable providers to use the same 0.5-mL dose for all recommended individuals.

<table>
<thead>
<tr>
<th>Vaccine*</th>
<th>Presentation</th>
<th>Age Group (Indication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluarix Quadrivalent</strong></td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td><strong>Flulaval Quadrivalent</strong></td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td></td>
<td>5-mL multidose vial (ten 0.5-mL doses)</td>
<td></td>
</tr>
</tbody>
</table>

*Fluarix and Flulaval are registered trademarks of the GSK group of companies.
Shifting the conversation from vaccine effectiveness to public health benefits

This year’s flu vaccine may only be 10% effective, experts warn

CDC: Flu vaccine is one of the least effective in years, but it still helps

Flu shot only 36 percent effective

Flu vaccine, even when just 20% effective, saves tens of thousands of lives

Flu vaccination prevents millions of illnesses, medical visits, hospitalizations and deaths annually

Even during seasons when vaccine effectiveness (VE) is reduced, vaccination reduces the number of influenza cases and severe outcomes

Overall VE of 19% can still lead to

- 1,419 Deaths averted
- 47,000 Hospitalizations averted
- 793,000 Medical visits averted
- 1.6 million Cases averted

**Assessing vaccine efficacy against clinically significant aspects of influenza**

D-QIV-004 study: Vaccine efficacy in children 6-35 months of age\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>Moderate-to-severe influenza</th>
<th>Any severity influenza</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluarix QIV efficacy (97.5% CI)</td>
<td>63% (52-72)</td>
<td>50% (42-57)</td>
</tr>
<tr>
<td>Fluarix QIV (N = 5707)</td>
<td>1.6% (90 cases)</td>
<td>4.3% (242 cases)</td>
</tr>
<tr>
<td>Control (N = 5697)</td>
<td>6.0% (344 cases)</td>
<td>11.6% (662 cases)</td>
</tr>
</tbody>
</table>

The “moderate-to-severe influenza” endpoint captures the more clinically significant outcomes of influenza\(^2\)


---

**GSK Flu: 2018-2019 season**

Simplifying flu vaccination for providers

GSK can now offer two flu vaccines that enable providers to use the same 0.5-mL dose for all recommended individuals.

<table>
<thead>
<tr>
<th>Vaccine*</th>
<th>Presentation</th>
<th>Age Group (Indication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluarix Quadrivalent</strong></td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td><strong>FluLaval Quadrivalent</strong></td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td></td>
<td>5-mL multidose vial (ten 0.5-mL doses)</td>
<td></td>
</tr>
</tbody>
</table>

GSK expects to supply approximately 40-45 million doses across both seasonal flu vaccines for the US market in the 2018-19 season.**

*Fluarix and FluLaval are registered trademarks of the GSK group of companies.
**Final quantities will be in demand & production capabilities

---
Thank you!

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

- Do not administer FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine.

- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

- Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

- If FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

- In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)

- Vaccination with FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients

GSK Flu 2018 Update